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Abstract
Background: Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), most likely linked to an impairment of
insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for
AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-lasting analogues of the GLP-1 incretin hormone
and are currently available to treat diabetes. They facilitate insulin signalling via the GLP-1 receptor (GLP-1R).
Numerous in vitro and in vivo studies have shown that GLP-1 analogues have a range of neuroprotective
properties. GLP-1Rs are expressed in the hippocampal area of the brain an important site of adult neurogenesis
and maintenance of cognition and memory formation. Therefore, if GLP-1 analogues can cross the blood brain
barrier, diffuse through the brain to reach the receptors and most importantly activate them, their neuroprotective
effects may be realized.
Results: In the present study we profiled the GLP-1 receptor agonists liraglutide (Victoza) and lixisenatide
(Lyxumia). We measured the kinetics of crossing the blood brain barrier (BBB), activation of the GLP-1R by
measuring cAMP levels, and physiological effects in the brain on neuronal stem cell proliferation and neurogenesis.
Both drugs were able to cross the BBB. Lixisenatide crossed the BBB at all doses tested (2.5, 25, or 250 nmol/kg bw
ip.) when measured 30 min post-injection and at 2.5-25 nmol/kg bw ip. 3 h post-injection. Lixisenatide also
enhanced neurogenesis in the brain. Liraglutide crossed the BBB at 25 and 250 nmol/kg ip. but no increase was
detectable at 2.5 nmol/kg ip. 30 min post-injection, and at 250 nmol/kg ip. at 3 h post-injection. Liraglutide and
lixisenatide enhanced cAMP levels in the brain, with lixisenatide being more effective.
Conclusions: Our results suggest that these novel incretin analogues cross the BBB and show physiological activity
and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.
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Background
Type 2 diabetes mellitus (T2DM) is characterized by
insulin resistance resulting in glucose intolerance and
hyperglycaemia [1].
Since insulin effectiveness is reduced in diabetes,
research into other signalling pathways that support
insulin actions or that reduce blood glucose is ongoing.
One of these strategies focus on the use of the incretins,
a class of peptide hormones that helps to normalise
insulin signaling and also improves blood sugar levels.
Incretins increase the release of insulin during high
blood sugar levels, the so-called ‘incretin effect’.D r u g s
that mimic incretin hormones can maintain glucose
homeostasis and improve multiple symptoms of type 2
diabetes like the risk of hypoglycaemia, inadequate post-
prandial blood glucose control, glucose fluctuations, b-
cell failure, and weight gain [1,2].
GLP-1 is an endogenous 30-amino acid peptide hor-
mone. Numerous novel long-lasting GLP-1 receptor
agonists have been developed by several companies.
Exendin-4 (Byetta) has been on the market as a T2DM
treatment for several years [3]. Liraglutide (Victoza) also
has been released onto the market several years ago [4].
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T2DM has been identified as a risk factor for AD,
indicating that insulin signaling failure may be a factor
in initiating or accelerating the development of AD. Epi-
demiological studies found a clear correlation between
T2DM and the risk of developing AD [6-8]. It was also
shown that insulin receptors in the brain are desensi-
tised in AD patients [9,10]. Therefore, a promising strat-
egy to treat AD is the use of such GLP-1 analogues
[11]. GLP-1 receptors are found on neurons in the
brains of rodents and humans [12,13]. The GLP-1
receptor agonists exendin-4, liraglutide, lixisenatide, and
(Val8)GLP-1 have neuroprotective properties. The pro-
tease resistant and long-lasting GLP-1 analogue Val(8)
GLP-1 enhanced synaptic plasticity in acute and chronic
application and preserved synaptic functionality in the
brains of a mouse model of AD [14,15]. The novel GLP-
1 analogue liraglutide lowered plaque formation, pro-
tected memory and synaptic plasticity, and reduced
inflammation in the brains of a mouse model of Alzhei-
mer disease [16]. All of these effects in the brain were
observed after peripheral injection. Therefore, it is likely
that these peptides have to be able to cross the blood
brain barrier (BBB).
The focus of this study was to measure the kinetics of
incretin drugs of crossing the blood brain barrier, activa-
tion of incretin receptors by measuring cAMP levels,




There were no significant levels of Liraglutide found 5
min post i.p. injection, in the brains of mice adminis-
tered with a 2.5 nmol/kg bw, 25 nmol/kg bw or 250
nmol/kg bw dose of the peptide (see Figure 1a). How-
ever, significant levels oft h eG L P - 1 Ra g o n i s tw e r e
f o u n da tb o t h3 0m i na n d3hp o s ti n j e c t i o nw i t ht h e
250 nmol/kg dose (p <0 . 0 1a n dp < 0.05 respectively).
The medium dose of 25 nmol/kg bw was also sufficient
to raise peptide levels in the brain 30 min post injection
(p < 0.05) but not after 3 h (Figure 1b and 1c). To
determine whether Liraglutide activates the GLP-1R in
the brain we measured total brain cAMP levels 30 min
post i.p. injection with 25 nmol/kg bw of the peptide.
cAMP is the second messenger of the GLP-1R. Signifi-
cant levels of cAMP (p < 0.05) were detected 30 min
post administration indicating GLP-1R activation (Figure
1d).
Figure 1 At 5 min post- ip. injection, there was no significant increase of liraglutide in the brains of mice (A). There was an increase in
liraglutide levels in the brains of mice injected with 25 or 250 nmol/kg bw at 30 min (B) and only those injected with the highest dose at 3 h
post-injection (C). Brain levels of cAMP were increased 30 min post injection with 25 nmol/kg bw ip.. * = p < 0.05. Values are the mean ± S.E.M.
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Lixisenatide was found in significant concentrations fol-
lowing administration with 2.5, 25 or 250 nmol/kg bw
of the peptide at 30 min post injection (p < 0.01, p <
0.05 and p < 0.05) (Figure 2a). Similarly at 3 h post
administration Lixisenatide was still present in a signifi-
cant amount in the brain 3 h post injection in the mice
given the 2 lower doses (p <0 . 0 5 ) ,h o w e v e r ,n o tw i t h
the highest dose due to huge variation within this parti-
cular group (Figure 2b). Interestingly, for this peptide
there is as much detected in the brain when adminis-
tered the lowest dose of 2.5 nmol/kg bw as with the
highest dose of 250 nmol/kg bw. Furthermore, there is
little or no decrease in the concentration of Lixisenatide
from 30 min to 3 h post injection.
There was a 1.8-fold increase in cell proliferation as
measured by BrdU analysis (p < 0.01, Figure 2c). Corre-
spondingly, there was a 1.7-fold increase (p < 0.05) in
young neurons as determined by Double Cortin analysis
(Figure 2d). The level of cAMP was inhanced in the
brains after injection with 25 nmol/kg bw ip. (p <0 . 0 1 ) ,
see Figure 2e. When directly comparing the effects of
liraglutide with lixisenatide, a significant difference
between drugs is found (p < 0.05, Figure 2f).
Discussion
We have investigated the GLP-1 receptor agonists Lira-
glutide and Lixisenatide. We have provided clear evi-
d e n c et h a tb o t hp e p t i d e sh a v et h ea b i l i t yt oc r o s st h e
BBB, as we found significantly elevated levels of these
peptides in the brain 30 min following i.p. injection. Lir-
aglutide levels in the brain were higher with increasing
doses injected ip. Also, there was a time-dependence as
only the highest dose injected showed a significant
increase in the brain after 3 h. The brain levels of
cAMP were increased, demonstrating the activation of
the GLP-1 receptor which is linked to an adenylate
cyclase [1]. Previous studies already had demonstrated
that liraglutide also enhances neuronal progenitor prolif-
eration and increased neurogenesis in the brain of a
mouse model of Alzheimer disease [16].
Lixisenatide also entered the brain in a sufficiently
detectable amount, even at the lowest dose tested of 2.5
nmol/kg bw. 30 min post-injection. At 3 h post-injec-
tion, the highest dose did not show a significant increase
in the brain. This observation suggests that the trans-
port across the BBB is highly regulated, and that this
transport system may shut down at doses that are
abnormally high. Similar observations have been made
previously when testing exendin-4 [17]. The brain levels
of cAMP were increased, demonstrating the activation
of the GLP-1 receptor. We were also able to demon-
strate that lixisenatide, when injected once daily for
3 weeks, promotes neuronal progenitor proliferation in
the dentate gyrus, and neurogenesis in the brain,
demonstrating that this drug not only crosses the BBB,
but also shows clear physiological effects in the brain.
Interestingly, lixisenatide is transported across the BBB
at a lower dose than liraglutide, and shows enhanced
cAMP at equal dose compared with liraglutide.
Our results show that incretin analogues can be
injected peripherally and are taken up into the brain
where they show physiological activity. Previous studies
have shown similar effects in the brain, in particular on
cell proliferation and neurogenesis [14,18-21], and our
results add considerably to those findings.
Exendin-4 is currently on the market as a T2DM
treatment and is injected peripherally twice-daily. Lira-
glutide is also on the market and is injected peripherally
once daily [1]. Lixisenatide is under development to be
used as a once-daily treatment for T2DM [5]. Such
d r u g sc a nb et a k e nb yn o n - d i a b e t i cp e o p l ea st h e yo n l y
affect blood sugar levels in hyperglycaemia [22].
Conclusion
If the improvements in memory and synaptic plasticity,
reduction in neurotoxic amyloid oligomer levels, num-
bers of amyloid plaques and of the inflammation
response, and increased neurogenesis observed in pre-
vious studies [11,23] translate to humans, GLP-1 analo-
gues such as Liraglutide or GLP-1 receptor agonists
such as exendin-4 and lixisenatide are promising new
treatment strategies for Alzheimer’s disease. Importantly,
clinical trials of the effects of exendin-4 in patients with
Parkinson’s disease (UCL, London, UK) have been
started, and clinical trials in patients with MCI or early-
phase AD are on their way (NIH/NIA, USA) (see an
update on http://www.clinicaltrials.gov). A third clinical





Each animal received saline by i.p. injection (0.9% (w,v)
NaCl) or liraglutide (2.5 nmol/kg body weight (bw), 25
nmol/kg bw or 250 nmol/kg bw) (female, C57/BL 6
background, n = 5 per group). At 5 min, 30 min or 3 h
post treatment the mice were painlessly killed with an
overdose of anaesthetic. Subsequently, animals were per-
fused with PBS in order to clear the circulation of all
blood. Each brain was weighed, placed in a Bijou tube,
snap frozen in liquid nitrogen and stored at -80 C until
further processing and analysis. All experiments were
licenced by the UK home office (Project licence No.
PPL2603b).
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Page 3 of 6Figure 2 (A) Lixisenatide levels in the brains at 30 min following i.p. (2.5, 25 or 250 nmol/kg body weight) injection were increased.
(B) Lixisenatide levels in the brains at 3 h following i.p. injection were only increased for the lower doses (2.5, 25 nmol/kg body weight). (C) The
number of neuronal progenitor cells in the dentate gyrus was increased after 3 weeks of ip injection 25 nmol/kg bw once-daily. (D) The number
of young neurons in the dentate gyrus was also increased. (E) The level of cAMP was enhanced in the brains after injection with 25 nmol/kg bw
ip. (F) When directly comparing the effects of liraglutide with lixisenatide, a significant difference between drugs is found.* = p < 0.05, ** = p <
0.01. Micrographs: BrdU stain: A Saline control B Lixisenatide treated, 3 weeks once daily i.p. injection. Blue arrows point to BrdU positively
stained cells. DCX stain: Doublecortin stained immature neurons in dentate gyrus. A Saline control B Lixisenatide treated, 3 weeks once daily i.p.
administration.
Hunter and Hölscher BMC Neuroscience 2012, 13:33
http://www.biomedcentral.com/1471-2202/13/33
Page 4 of 6Acid ethanol extraction of liraglutide from mouse brains
Tubes containing the brains from the mice were
r e m o v e df r o ms t o r a g ea n dk e p ti nl i q u i dn i t r o g e n .E a c h
tube was processed one at a time to avoid thawing. 2.5
ml of acid ethanol (75% ethanol, 1.5% conc HCl)/g of
tissue was added and the sample sonicated using a Soni-
prep 150 plus HSE (Davidson and Harley Ltd). Samples
were stored on ice before centrifugation at 10,000 rpm
for 15 min at 4 C using the Beckman centrifuge. The
supernatant was poured off into fresh eppendorf tubes.
300 μl of the supernatant was removed to a clean
eppendorf tube and 300 μlo f1MT r i s( p H7 . 6 )w a s
added. These samples were then dried down in a Speed-
vac at 45 C for 1 h 30 min to completely remove the
liquid. Samples were reconstituted in GLP-1 ELISA kit
assay buffer (Millipore, MA, USA).
ELISA analysis of brain samples
The GLP-1 (Active) 96 well fluorescent ELISA kit
(EGLP-35 K, Millipore, MA, USA) was used to measure
the Liraglutide levels detected in the brain samples. The
assay was performed according to the manufacturers
instructions. Briefly, the plate was incubated with wash
buffer for 5 min then decanted and the excess removed
by tapping on absorbent towels. Assay buffer was added
to all wells followed by either the standards, quality con-
trols or samples in the appropriate order on the plate.
The plate was covered with a plate sealer, gently shaken
then incubated overnight at 4
°C. On day 2 the plate was
washed 5 times with wash buffer, detection conjugate
a d d e da n di n c u b a t e da tr o o mt e m p e r a t u r ef o r2h .T h e
plate was then washed 3 times and diluted substrate
added and allowed to incubate in the dark for 18 min.
Stop solution was added and the plate read at 355 nm/
460 nm using the Flexstation 3 and Softmax pro-
gramme. Brain samples were diluted 1:10 prior to mea-
surement on the plate so results were adjusted
accordingly following analysis.
cAMP analysis of brain samples (for both experiments)
Each brain was extracted using 0.1 M HCl. 10 ml of 0.1
M HCl per g of tissue was added. Samples were soni-
cated then centrifuged at 10,000 rpm for 15 min at 4
°C.
The supernatent was poured off and used directly for
measurement by ELISA. Dilutions were made using the
0.1 M HCl provided in the kit. Brain cAMP levels were
measured using the direct cAMP ELISA kit (Enzo Life
Sciences) according to the manufacturers instructions.
Experiment 2
We examined the concentration of Lixisenatide found in
the brains of female WT mice following i.p. administra-
tion of 2.5, 25 or 250 nmol/kg bw of the peptide at 30
min and 3 h post injection. We also undertook a 3 week
study on the effect of 25 nmol/kg bw daily
administration of Lixisenatide on cell proliferation and
new neuron development in the brains of WT mice.
Animals
In the chronic study, one group of female WT mice (n =
6) received once daily Lixisenatide (25 nmol/kg bw) for 3
weeks and the other group (n = 6) received saline (0.9%
(w,v) NaCl) as control. At the end of the treatment period
the mice were painlessly killed with an overdose of anaes-
thetic. Subsequently, animals were perfused with PBS,
then with paraformaldehyde (PFA). Each brain was divided
into 2 hemispheres, stored in PFA and kept at 4°C until
further processing and analysis. In order to perform BrdU
immunohistological analysis, animals were injected with 5-
Bromo-2-DeoxyUridine (BrdU) (50 mg/kg) 24 h prior to
sacrificing. Acid ethanol extraction of Lixisenatide from
mice brains was performed as described above.
ELISA analysis of brain samples
Analysis of the Lixisenatide treated brains was carried
out as recommended by the manufacturer of the total
GLP-1 (7-36 and 9-36) ELISA kit, 43-GPTHU-E01,
( A l p c o .N H ,U S A ) .B r i e f l y ,s t a n d a r d s ,c o n t r o l sa n dt e s t
samples were added to the designated wells and then
antibody mixture was added to each of these wells. The
plate was sealed and incubated overnight at 4
°C. Con-
tents were then removed and the plate washed 5 times
before adding HRP substrate. The plate was protected
from exposure to light and incubated at RT for 20 min.
Stop solution was then added, mixed gently and the
absorbance read at 450 nm/620 nm within 10 min.
Cryostat preparation of brain tissue
One hemisphere from each animal was transferred from
the PFA and placed in 30% sucrose solution overnight at
4
°C. Each hemisphere was then mounted on the specimen
disc using tissue-tek and Envi Ro Tech freeze spray. Brain
sections were cut at 45 μm and placed in cryoprotect solu-
tion. Every sixth section was taken for analysis.
BrdU Immunohistochemical analysis
Cryoprotection solution was removed and sections
washed in diH2O then incubated in H2O2. Sections were
rinsed in H2O then incubated in 0.3% Triton X for 15
min. Following this sections were washed in PBS, incu-
bated in HCl, then incubated in Borax, washed again in
PBS then blocked in normal horse serum before incubat-
ing with the primary BrdU antibody (1:200) overnight at
4
°C. On day 2 the sections were washed in PBS, incu-
bated with the secondary antibody (anti-mouse, 1:200)
for 30 min, washed in PBS, incubated in ABC reagent
(Vector ABC Elite kit mouse) for 30 min, washed in PBS
then SG substrate added until sufficient colour developed
(2-10 min). Sections were then mounted on silanized
slides. The total number of BrdU positive cells in the
dentate gyrus were counted following stereological rules.
Every 6
th section was selected and 8 sections were stained
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culated. There were 6 animals in each treatment group.
Therefore, the overall average per group was then calcu-
lated. The values are the average number of cells per ani-
mal. The doublecortin stained neurons were counted by
the same method so they are also expressed as the aver-
age number per animal.
BrdU is a pyrimidine analogue of thymidine, it is
selectively incorporated into the DNA of cells during
the S phase of the cell cycle, therefore, it is an indicator
of proliferating cells.
Double Cortin (DCX) immunohistological analysis
Excess cryoprotection solution was removed, sections
washed in PBS, incubated in H2O2, washed in PBS,
blocked in rabbit serum (5%) for 1 h then incubated in pri-
mary antibody (goat anti-DCX, 1:200) overnight at 4 C.
The following day the sections were washed in PBS, incu-
bated in secondary antibody (Vecta ABC kit anti-goat,
1:400) for 90 min, washed in PBS, incubated in ABC
reagent for 90 min, washed in PBS, incubated in SG sub-
strate until sufficient colour developed, then finally washed
in diH2O before being mounted on salinized slides. DCX
is a microtubule associated protein expressed almost
exclusively in immature neurons. The number of new neu-
rons observed on each section were counted and at least 8
sections were analysed per animal.
Statistical analysis
Results were analysed using Prism Graphpad software.
Values are expressed as the mean ± SEM. Data was
assessed using Students t-test and values were consid-
ered statistically significant if p < 0.05.
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